Below The Knee | Market Signal

Twenty-five years since September 11, 2001. Having been in the military before, during and after - it has left a profound impact. Many friends answered the call that day and the years that followed. Some never came home. Some came home changed. The impact rippled through families, communities, and countless lives — a wound that doesn't close, only deepens in meaning as time passes.

Today I remember.

When IPAWS Takes Center Stage: Capital Moves, DME Scrutiny, and Specialist Momentum Converge

This is IPAWS week at the Ritz-Carlton in New Orleans. Below The Knee is Official Market Intelligence Partner. The meetings have been strong, and we'll have a full recap once Friday's sessions wrap. After IPAWS closes, we're heading straight to NAWCO HEAL next week — conference season in full swing.

But the market doesn't pause between meetings.

While wound care clinicians and medtech executives gather in New Orleans, large-cap balance sheets are being recalibrated and reimbursement screws are tightening. Smith+Nephew raised $700 million in bonds to refinance its 2030 notes, extending debt maturity and managing liquidity during its turnaround. Zimmer Biomet is restructuring its Americas leadership and overhauling its 2,500-person U.S. sales force, converting independent contractors to dedicated specialists effective October 1. Both moves signal large-cap companies executing structural change, not responding to near-term tailwinds.

CMS is intensifying scrutiny on durable medical equipment suppliers as part of a broader anti-fraud initiative. For wound care and vascular medtech, this hits NPWT, offloading devices, and compression therapy — all frequently billed under DME codes and subject to audit and compliance risk. Increased CMS enforcement could affect reimbursement pathways and supplier contracting strategies across BTK.

But specialists are advancing momentum.

MediWound is presenting at H.C. Wainwright Conference this week (September 14-16) with Phase III VALUE trial enrollment across 40 sites in U.S., Europe, and Israel for EscharEx chronic wound debridement therapy. Abbott presented positive 12-month ablation data for TactiFlex Duo at ESC 2026 Congress in Munich — 74.6% of patients remaining free from documented arrhythmias and repeat procedures, supporting FDA approval pathway. Integra LifeSciences presenting at Wells Fargo (September 9) and Morgan Stanley (September 15) healthcare conferences, positioning strategic initiatives and market outlook. Solventum participating in Wells Fargo healthcare conference fireside chat on September 9, discussing market trends and strategic direction.

The story this week is bifurcation at different time scales. Large-cap balance sheet and sales force restructuring is medium-term strategic work. DME scrutiny is immediate reimbursement pressure. Specialist pipeline advancement (MediWound Phase III, Abbott cardiac data, Integra/Solventum investor positioning) is mid-cycle momentum.

When capital is restructuring and reimbursement is tightening, specialists with clear pipelines and defined use cases outperform generalists managing structural change.

IPAWS presentations and product updates wrapping Friday. Full conference coverage coming after we digest the week.

Regulatory | CMS Intensifies DME Supplier Scrutiny as Part of Anti-Fraud Push

CMS has intensified scrutiny on durable medical equipment suppliers as part of a broader anti-fraud initiative. This regulatory pressure on DME suppliers is significant for the wound care and vascular medtech markets, as products like NPWT, offloading devices, compression therapy, and wound care supplies are frequently billed under DME codes and subject to audit and compliance risk. Increased CMS enforcement could affect reimbursement pathways, supplier contracting strategies, and billing compliance across the BTK space.

The BTK read: CMS DME pressure is the sequel to CAMP enforcement escalation. The agency is systematically tightening billing oversight across high-risk categories. For medtech companies and DME suppliers, compliance frameworks just became table stakes. Expect more audits, more documentation requirements, and faster enforcement against outliers. Companies with defensible billing practices and clear clinical documentation will outperform those playing at the margins.

Financial | Smith+Nephew Raises $700M in Bonds to Refinance 2030 Notes

Smith+Nephew raised $700 million through a bond issuance to refinance its existing 2030 notes, signaling active balance sheet management amid ongoing operational restructuring. This capital markets activity indicates the company is extending its debt maturity profile and managing liquidity as it continues its 12-point turnaround strategy. For the wound care and vascular medtech market, this suggests Smith+Nephew is securing financial flexibility to sustain investment in key BTK segments including advanced wound management and surgical reconstruction.

The BTK read: SNN's refinance is balance sheet recalibration, not panic. The company is extending debt maturity to align with turnaround timeline. This buys runway for execution on PICO NPWT geographic expansion, Integrity Orthopaedics integration, and CAMP pricing adaptation.

Market | Zimmer Biomet Restructures Americas Leadership and Overhauls Sales Force

Zimmer Biomet restructured its Americas leadership team and announced a commercial overhaul effective October 1, 2026. The company is replacing independent contractor sales representatives with fully dedicated specialists across its 2,500-person U.S. sales force. Three executives were promoted and one position was eliminated as part of the streamlining. While not directly a wound care or vascular play, Zimmer's commercial restructuring signals broader orthopedic and biosurgery market dynamics relevant to lower limb reconstruction and adjacent BTK categories.

The BTK read: Zimmer's contractor-to-dedicated shift is commercial model recalibration. Replacing independent reps with employed specialists costs more but gives the company direct control over market strategy and customer relationships. For lower limb reconstruction and foot & ankle markets, this could affect contracting dynamics and market access strategies.

Clinical | Abbott TactiFlex Duo Shows Positive 12-Month Ablation Data for Complex AFib

Abbott announced favorable 12-month safety and effectiveness data for its investigational TactiFlex Duo dual-energy ablation catheter, presented at ESC 2026 Congress in Munich. The device combines pulsed field ablation (PFA) and radiofrequency energy for treating complex atrial fibrillation cases, with 74.6% of patients remaining free from documented arrhythmias and repeat procedures. Results support FDA approval pathway for this cardiac electrophysiology device.

The BTK read: Abbott's TactiFlex Duo is adjacent to BTK vascular intervention markets. While cardiac EP, the dual-energy ablation technology could have applications in vascular access preservation and complex vascular intervention. The 12-month durability data is the clinical proof point.

Clinical | MediWound Advances EscharEx Phase III VALUE Trial Across 40 Sites

MediWound announced that CEO Ofer Gonen will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference September 14-16. The company is advancing its Phase III VALUE trial for EscharEx chronic wound debridement therapy with enrollment across 40 sites in U.S., Europe, and Israel.

The BTK read: MediWound's 40-site VALUE trial enrollment is pipeline momentum. Enzymatic debridement for chronic wounds is differentiated category with clear clinical use case. Watch for investor reception at H.C. Wainwright and whether partnership or funding opportunities emerge.

Market | Integra LifeSciences Presents at Wells Fargo and Morgan Stanley Conferences

Integra LifeSciences announced presentations at the Wells Fargo HealthCare Conference on September 9 and the Morgan Stanley Healthcare Conference on September 15. Leadership including CFO, Chief Commercial Officer, and CEO will discuss strategic initiatives and market outlook with institutional investors.

The BTK read: Integra's dual-conference circuit is strategic positioning. Back-to-back investor meetings signal active management of investor narrative around M&A, organic growth strategy, and market opportunities in skin substitutes and advanced wound dressings.

Market | Solventum Participates in Wells Fargo Healthcare Conference

Solventum management participated in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, discussing healthcare market trends and strategic direction with investors and industry stakeholders. Solventum, spun off from 3M in 2024, is a key player in advanced wound care and NPWT markets.

The BTK read: Solventum at Wells Fargo is investor confidence check. Commentary on market trends and strategic priorities will signal whether the spinoff HIS separation narrative is gaining traction with capital.

Woundcare, Limb Salvage, Foot and Ankle and Vascular, all scored, indexed and monitored. Real-time capital signals. Curated news and alerts. AI-powered queries. The way no market intelligence platform has done before.

intelligence.belowtheknee.co/sign-up →

Strong meetings this week at IPAWS in New Orleans. Full conference recap coming after Friday's sessions wrap. We're heading straight to NAWCO HEAL next week to keep the momentum going.

If you're at either event, find us. Email [email protected].

September 14–16 | New York City — H.C. Wainwright 28th Annual Global Investment Conference

September 15 | New York City — Morgan Stanley Healthcare Conference

September 14–16 | Louisville, KY — NAWCO HEAL Conference 2026 (BTK attending)

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026 – World Union of Wound Healing Societies Congress — Kuala Lumpur Convention Centre

October 1–4 | Bengaluru, India — DFSICON 2026 — Hilton Garden Inn Bengaluru, Embassy Manyata Business Park

October 8–10 | New Delhi, India — ASVS–VSICON 2026 — Pullman & Novotel New Delhi Aerocity

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

See you at HEAL,

-Scott